About CVRx, Inc.
https://www.cvrx.comCVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.
CEO
Kevin Hykes
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Lake Street
Buy
Craig-Hallum
Buy
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
JP Morgan
Underweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JOHNSON & JOHNSON
Shares:4.1M
Value:$24.83M
JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Shares:3.5M
Value:$21.15M
NEA MANAGEMENT COMPANY, LLC
Shares:2.03M
Value:$12.26M
Summary
Showing Top 3 of 102
About CVRx, Inc.
https://www.cvrx.comCVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.69M ▲ | $25.02M ▼ | $-12.87M ▲ | -87.61% ▲ | $-0.49 ▲ | $-11.2M ▲ |
| Q2-2025 | $13.59M ▲ | $25.83M ▲ | $-14.74M ▼ | -108.44% ▲ | $-0.57 ▼ | $-13.07M ▼ |
| Q1-2025 | $12.35M ▼ | $23.75M ▲ | $-13.77M ▼ | -111.48% ▼ | $-0.53 ▼ | $-12.13M ▼ |
| Q4-2024 | $15.34M ▲ | $23.32M ▼ | $-10.65M ▲ | -69.42% ▲ | $-0.43 ▲ | $-9.02M ▲ |
| Q3-2024 | $13.37M | $24.14M | $-13.1M | -97.95% | $-0.57 | $-11.93M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $85.12M ▼ | $111.33M ▼ | $63.27M ▲ | $48.05M ▼ |
| Q2-2025 | $95.03M ▼ | $119.56M ▼ | $61.63M ▲ | $57.93M ▼ |
| Q1-2025 | $102.67M ▼ | $129.59M ▼ | $60.23M ▼ | $69.36M ▼ |
| Q4-2024 | $105.93M ▲ | $133.41M ▲ | $62.36M ▼ | $71.06M ▲ |
| Q3-2024 | $100.16M | $127.67M | $62.49M | $65.18M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.87M ▲ | $0 ▲ | $0 ▲ | $0 ▼ | $-95.03M ▼ | $0 ▲ |
| Q2-2025 | $-14.74M ▼ | $-7.94M ▲ | $-103K ▲ | $392K ▼ | $-7.64M ▼ | $-8.04M ▲ |
| Q1-2025 | $-13.77M ▼ | $-12.77M ▼ | $-114K ▼ | $9.62M ▼ | $-3.27M ▼ | $-12.88M ▼ |
| Q4-2024 | $-10.65M ▲ | $-8.01M ▲ | $-52K ▼ | $13.83M ▼ | $5.77M ▼ | $-8.06M ▲ |
| Q3-2024 | $-13.1M | $-10.41M | $-37K | $40.2M | $29.76M | $-10.45M |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Countries | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 GERMANY | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Kevin Hykes
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Canaccord Genuity
Buy
Lake Street
Buy
Craig-Hallum
Buy
Cantor Fitzgerald
Overweight
Piper Sandler
Overweight
JP Morgan
Underweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JOHNSON & JOHNSON
Shares:4.1M
Value:$24.83M
JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Shares:3.5M
Value:$21.15M
NEA MANAGEMENT COMPANY, LLC
Shares:2.03M
Value:$12.26M
Summary
Showing Top 3 of 102